Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?

Cas J. Isfordink, Raoel Maan, Robert A. de Man, Karel J. van Erpecum, Adriaan J. van der Meer*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Downloads (Pure)

Abstract

Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis. Current guidelines recommend HCC and gastroesophageal varices (GEV) surveillance in patients with HCV infection and cirrhosis. However, since the recent introduction of direct-acting antivirals, most patients with cirrhosis are now cured of their chronic HCV infection. As virological cure is considered to substantially reduce the risk of cirrhosis-related complications, this review discusses the current literature concerning the surveillance of HCC and GEV in patients with HCV-induced cirrhosis with a focus on the setting following sustained virological response.

Original languageEnglish
Pages (from-to)6-14
Number of pages9
JournalEuropean Journal of Internal Medicine
Volume94
Early online date23 Sep 2021
DOIs
Publication statusPublished - 1 Dec 2021

Fingerprint

Dive into the research topics of 'Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?'. Together they form a unique fingerprint.

Cite this